Eloctate

Pharma

Sanofi takes $2B hemophilia write-down

It’s been just 16 months since Sanofi closed its Bioverativ buy, but it's already revising its sales projections for one of Bioverativ’s key products.

Carly Helfand Jul 29, 2019 11:51am

Sanofi's Eloctate suffers on Roche's Hemlibra launch

Apr 26, 2019 12:23pm

How can new launches mimic Keytruda, Harvoni and Opdivo?

Nov 16, 2017 10:23am

Biogen posts Q4 sales miss, issues 'conservative' 2017 guidance

Jan 26, 2017 10:47am